Alan S. Gamis
About
Alan S. Gamis is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Alan S. Gamis has authored 222 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Hematology, 78 papers in Molecular Biology and 76 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Alan S. Gamis's work include Acute Myeloid Leukemia Research (162 papers), Acute Lymphoblastic Leukemia research (70 papers) and Hematopoietic Stem Cell Transplantation (34 papers). Alan S. Gamis is often cited by papers focused on Acute Myeloid Leukemia Research (162 papers), Acute Lymphoblastic Leukemia research (70 papers) and Hematopoietic Stem Cell Transplantation (34 papers). Alan S. Gamis collaborates with scholars based in United States, Canada and Switzerland. Alan S. Gamis's co-authors include Todd A. Alonzo, Robert B. Gerbing, Soheil Meshinchi, Susana C. Raimondi, Betsy Hirsch, Richard Aplenc, Lillian Sung, Franklin O. Smith, Michael R. Loken and William G. Woods and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Alan S. Gamis
212 papers receiving 4.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alan S. Gamis United States | 41 | 3.1k | 1.7k | 1.6k | 1.1k | 696 | 222 | 5.0k | ||
| Joseph Brandwein Canada | 40 | 2.7k 0.9× | 1.2k 0.7× | 1.8k 1.1× | 1.8k 1.6× | 646 0.9× | 191 | 5.3k | ||
| James H. Feusner United States | 39 | 2.5k 0.8× | 1.4k 0.9× | 2.7k 1.7× | 1.3k 1.2× | 954 1.4× | 149 | 6.1k | ||
| Ursula Creutzig Germany | 53 | 5.2k 1.7× | 3.0k 1.8× | 2.5k 1.5× | 1.8k 1.6× | 812 1.2× | 217 | 7.6k | ||
| Edward A. Copelan United States | 31 | 3.9k 1.2× | 1.3k 0.8× | 878 0.5× | 1.4k 1.3× | 658 0.9× | 194 | 5.7k | ||
| Bruce Bostrom United States | 44 | 2.1k 0.7× | 2.9k 1.8× | 1.2k 0.7× | 1.1k 1.0× | 1.9k 2.7× | 129 | 6.0k | ||
| Joseph Mirro United States | 35 | 2.7k 0.9× | 2.0k 1.2× | 1.2k 0.7× | 822 0.7× | 497 0.7× | 93 | 4.7k | ||
| Mahmoud Aljurf Saudi Arabia | 36 | 2.3k 0.7× | 1.0k 0.6× | 609 0.4× | 1.2k 1.1× | 433 0.6× | 234 | 4.3k | ||
| Albert Oriol Spain | 41 | 4.8k 1.5× | 1.2k 0.7× | 3.2k 2.0× | 3.1k 2.8× | 426 0.6× | 313 | 6.9k | ||
| David D. Hurd United States | 35 | 2.4k 0.8× | 734 0.4× | 1.2k 0.7× | 1.6k 1.4× | 179 0.3× | 159 | 4.8k | ||
| Ajay Vora United Kingdom | 44 | 3.3k 1.1× | 4.5k 2.7× | 887 0.5× | 1.3k 1.1× | 2.8k 4.1× | 184 | 6.7k |
Countries citing papers authored by Alan S. Gamis
Since
Specialization
Citations
This map shows the geographic impact of Alan S. Gamis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan S. Gamis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan S. Gamis more than expected).
Fields of papers citing papers by Alan S. Gamis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alan S. Gamis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan S. Gamis. The network helps show where Alan S. Gamis may publish in the future.
Co-authorship network of co-authors of Alan S. Gamis
This figure shows the co-authorship network connecting the top 25 collaborators of Alan S. Gamis. A scholar is included among the top collaborators of Alan S. Gamis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan S. Gamis. Alan S. Gamis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Abla, Oussama, Rhonda E. Ries, Timothy J. Triche, et al.. (2024). Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Advances. 8(8). 2005–2017.
2.
Tarlock, Katherine, Robert B. Gerbing, Rhonda E. Ries, et al.. (2024). Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Advances. 8(9). 2094–2103.
3.
Farrar, Jason E., Jenny L. Smith, Megan Othus, et al.. (2023). Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology. 41(16). 2949–2962.
4.
Andolina, Jeffrey R., Yi‐Cheng Wang, Lingyun Ji, et al.. (2022). Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience. Bone Marrow Transplantation. 57(3). 445–452.
5.
Pollard, Jessica A., Erin Guest, Todd A. Alonzo, et al.. (2021). Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology. 39(28). 3149–3160.
6.
Tarlock, Katherine, Todd A. Alonzo, Yi-Cheng Wang, et al.. (2019). Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clinical Cancer Research. 25(16). 5038–5048.
7.
August, Keith J., et al.. (2019). Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatric Blood & Cancer. 67(3). e28062–e28062.
8.
Tarlock, Katherine, Todd A. Alonzo, Michael R. Loken, et al.. (2017). Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 23(14). 3649–3656.
9.
Cooper, Todd M., Rhonda E. Ries, Todd A. Alonzo, et al.. (2017). Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood. 130. 407–407.
10.
Chauhan, Lata, Todd A. Alonzo, Jim J. Wang, et al.. (2017). Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial. Blood. 130. 2526.
11.
Brown, Fiona C., Paolo Cifani, Esther Drill, et al.. (2016). Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology. 176(1). 86–91.
12.
Farrar, Jason E., Rhonda E. Ries, Daniel Wai, et al.. (2016). Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research. 76(8). 2197–2205.
13.
Farrar, Jason E., Hamid Bolouri, Rhonda E. Ries, et al.. (2016). Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative. Blood. 128(22). 595–595.
14.
Laszlo, George S., Todd A. Alonzo, Chelsea J. Gudgeon, et al.. (2015). Multimerin-1 ( MMRN1 ) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 21(14). 3187–3195.
15.
Tarlock, Katherine, Todd A. Alonzo, Robert B. Gerbing, et al.. (2015). Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3 /ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(8). 1951–1957.
16.
Gamis, Alan S., Todd A. Alonzo, Soheil Meshinchi, et al.. (2014). Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology. 32(27). 3021–3032.
17.
Alonzo, Todd A., Roland B. Walter, Robert B. Gerbing, et al.. (2013). Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy. Clinical Cancer Research. 19(6). 1620–1627.
18.
McCune, Jeannine S., Meagan J. Bemer, Jeffrey S. Barrett, et al.. (2013). Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization. Clinical Cancer Research. 20(3). 754–763.
19.
Ho, Phoenix A., Todd A. Alonzo, Robert B. Gerbing, et al.. (2013). High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. British Journal of Haematology. 162(5). 670–677.
20.
Gamis, Alan S., Richard Aplenc, Todd A. Alonzo, et al.. (2013). Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531. Blood. 122(21). 355–355.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Joseph Brandwein Breakdown of academic impact, for papers by James H. Feusner Breakdown of academic impact, for papers by Ursula Creutzig Breakdown of academic impact, for papers by Edward A. Copelan Breakdown of academic impact, for papers by Bruce Bostrom Breakdown of academic impact, for papers by Joseph Mirro Breakdown of academic impact, for papers by Mahmoud Aljurf Breakdown of academic impact, for papers by Albert Oriol Breakdown of academic impact, for papers by David D. Hurd Breakdown of academic impact, for papers by Ajay Vora